title: Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER.
abstract: It has been 20years that the G protein-coupled estrogen receptor (GPER) was cloned as the orphan receptor GPR30 from multiple cellular sources, including vascular endothelial cells. Here, I will provide an overview of estrogen biology and the historical background leading to the discovery of rapid vascular estrogen signaling. I will also review the recent advances in the understanding of the mechanisms underlying GPER function, its role in physiology and disease, some of the currently available GPER-targeting drugs approved for clinical use such as SERMs (selective estrogen receptor modulators) and SERDs (selective estrogen receptor downregulators). Many of currently used drugs such as tamoxifen, raloxifene, or faslodex™/fulvestrant were discovered targeting GPER many years after they had been introduced to the clinics for entirely different purposes. This has important implications for the clinical use of these drugs and their modes of action, which I have termed 'reverse translational medicine'. In addition, environmental pollutants known as 'endocrine disruptors' have been found to bind to GPER. This article also discusses recent evidence in these areas as well as opportunities in translational clinical medicine and GPER research, including medical genetics, personalized medicine, prevention, and its theranostic use.
authors.affiliation: Molecular Internal Medicine, University of Zürich, Switzerland. Electronic address: barton@access.uzh.ch.
authors.forename: Matthias
authors.initials: M
authors.lastname: Barton
mesh_terms: D000818:Animals; D004965:Estrogen Antagonists / Q000494:pharmacology; D006801:Humans; D008954:Models, Biological; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors / Q000378:metabolism*; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000378:metabolism*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D043562:Receptors, G-Protein-Coupled; D020845:Selective Estrogen Receptor Modulators
keywords: Atherosclerosis; Autoimmune disease; Blood pressure; Cancer; Clinical medicine; Coronary artery disease; Dyslipidemia; Faslodex™; Fulvestrant; GPER-1; GPR30; Hypertension; ICI 182,780; Inflammation; Niacin; Patients; Raloxifene; Tamoxifen; Theranostics; Translational medicine